Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G J Yuen

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Antimicrobial Agents and Chemotherapy|April 17, 2001
Short-term measures of relative efficacy predict longer-term reductions in human immunodeficiency virus type 1 RNA levels following nelfinavir monotherapyJ Mittler, P Essunger, G J Yuen, et al.
Pharmacotherapy|April 20, 2001
A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adultsA C Crémieux, C Katlama, C Gillotin, et al.
Antimicrobial Agents and Chemotherapy|June 1, 1996
Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunctionA E Heald, P H Hsyu, G J Yuen, et al.
Annals of Internal Medicine|April 1, 1992
Relationship between dideoxyinosine exposure, CD4 counts, and p24 antigen levels in human immunodeficiency virus infection. A phase I trialG L Drusano, G J Yuen, J S Lambert, et al.
Journal of Clinical Pharmacology|December 1, 1995
Pharmacokinetics, absolute bioavailability, and absorption characteristics of lamivudineG J Yuen, D M Morris, P K Mydlow, et al.
Antimicrobial Agents and Chemotherapy|December 3, 1999
Population pharmacokinetics of lamivudine in adult human immunodeficiency virus-infected patients enrolled in two phase III clinical trialsK H Moore, G J Yuen, E K Hussey, et al.
Journal of Clinical Pharmacology|March 28, 2001
Abacavir/lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with each component administered concurrently and the effect of food on absorptionG J Yuen, Y Lou, N F Thompson, et al.
Clinical Pharmacology and Therapeutics|May 1, 1996
Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazoleK H Moore, G J Yuen, R H Raasch, et al.
Antimicrobial Agents and Chemotherapy|October 1, 1995
Population differences in ganciclovir clearance as determined by nonlinear mixed-effects modellingG J Yuen, G L Drusano, C Fletcher, et al.
Antimicrobial Agents and Chemotherapy|June 1, 1992
Impact of bioavailability on determination of the maximal tolerated dose of 2',3'-dideoxyinosine in phase I trialsG L Drusano, G J Yuen, G Morse, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Antimicrobial Agents and Chemotherapy|April 17, 2001
Short-term measures of relative efficacy predict longer-term reductions in human immunodeficiency virus type 1 RNA levels following nelfinavir monotherapyJ Mittler, P Essunger, G J Yuen, et al.
Pharmacotherapy|April 20, 2001
A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adultsA C Crémieux, C Katlama, C Gillotin, et al.
Antimicrobial Agents and Chemotherapy|June 1, 1996
Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunctionA E Heald, P H Hsyu, G J Yuen, et al.
Annals of Internal Medicine|April 1, 1992
Relationship between dideoxyinosine exposure, CD4 counts, and p24 antigen levels in human immunodeficiency virus infection. A phase I trialG L Drusano, G J Yuen, J S Lambert, et al.
Journal of Clinical Pharmacology|December 1, 1995
Pharmacokinetics, absolute bioavailability, and absorption characteristics of lamivudineG J Yuen, D M Morris, P K Mydlow, et al.
Antimicrobial Agents and Chemotherapy|December 3, 1999
Population pharmacokinetics of lamivudine in adult human immunodeficiency virus-infected patients enrolled in two phase III clinical trialsK H Moore, G J Yuen, E K Hussey, et al.
Journal of Clinical Pharmacology|March 28, 2001
Abacavir/lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with each component administered concurrently and the effect of food on absorptionG J Yuen, Y Lou, N F Thompson, et al.
Clinical Pharmacology and Therapeutics|May 1, 1996
Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazoleK H Moore, G J Yuen, R H Raasch, et al.
Antimicrobial Agents and Chemotherapy|October 1, 1995
Population differences in ganciclovir clearance as determined by nonlinear mixed-effects modellingG J Yuen, G L Drusano, C Fletcher, et al.
Antimicrobial Agents and Chemotherapy|June 1, 1992
Impact of bioavailability on determination of the maximal tolerated dose of 2',3'-dideoxyinosine in phase I trialsG L Drusano, G J Yuen, G Morse, et al.
Pageof 3